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Background. Polymyxins have re-entered use against problem Gram-negative 36 
bacteria. Resistance rates are uncertain, with estimates confounded by selective testing. 37 
Methods. The BSAC Resistance Surveillance Programme has routinely tested colistin 38 
since 2010; we reviewed data up to 2017 for relevant Enterobacterales (n=10,914). 39 
Unexpectedly frequent resistance was seen among the Enterobacter cloacae complex 40 
isolates (n=1749); for these, we investigated relationships to species, genome, carbon 41 
source utilisation and LPS structure. Results. Annual colistin resistance rates among E. 42 
cloacae complex isolates were 4.4% to 20%, with a rising trend among bloodstream 43 
organisms; in contrast, annual rates for Escherichia coli, Klebsiella spp. and E. 44 
aerogenes generally remained <2%. WGS split the E. cloacae complex isolates into 7 45 
Genogroup clusters, designated A-G. Among isolates assigned to Genogroups A-D, 46 
47/50 sequenced were colistin resistant, and many, from Genogroups A-C identified as 47 
E. asburiae. Isolates belonging to Genogroups E-G consistently identified as E. cloacae 48 
and were rarely (only 3/45 representatives sequenced) colistin resistant. Genogroups F 49 
and G – the predominant colistin-susceptible clusters – were metabolically distinct from 50 
other clusters, notably regarding utilisation or not of L-fucose, formic acid, D-serine, 51 
adonitol, myo-inositol, L-lyxose and polysorbates. LPS from resistant organisms grown 52 
without colistin pressure lacked substitutions with 4-amino-arabinose or ethanolamine 53 
but was more structurally complex, with more molecular species present. Conclusions. 54 
Colistin resistance is frequent in the E. cloacae complex and increasing among 55 
bloodstream isolates. It is associated with: (i) particular genomic and metabolic clusters, 56 
(ii) identification as E. asburiae and (iii) with more complex LPS architectures. 57 
Introduction 58 
After long abandonment, intravenous polymyxins have re-emerged as treatments for 59 
infections due to multidrug-resistant Gram-negative bacteria.1,2 Colistin (polymyxin E) 60 
is also used as a nebulised agent for chronic pulmonary infections with Pseudomonas 61 
aeruginosa,3 and as a non-absorbed oral agent in selective digestive decontamination.4   62 
Polymyxins have multiple effects, but primarily bind to negatively-charged 63 
lipid A residues in the LPS, destabilising the outer membrane and promoting their own 64 
uptake.5 Resistance is inherent in Proteeae, Serratia spp. and Burkholderia spp., which 65 
add positively-charged sugars (4-amino-L-arabinose, Ara4N) or amino-alcohols 66 
(ethanolamine) to their LPS, preventing polymyxin binding.1,2,5 Resistance arises in 67 
other Enterobacterales via chromosomal mutations up-regulating systems that similarly 68 
modify the lipid A, or through acquisition of plasmids carrying mcr genes, encoding 69 
phosphoethanolamine transferases recruited, at least in the case of mcr1 and mcr2, by 70 
horizontal transfer from Moraxella spp.6,7    71 
The prevalence of colistin resistance in the UK and worldwide is uncertain and 72 
subject to detection bias because many laboratories only test the drug against bacteria 73 
resistant to standard agents. Moreover, mutational resistance is often unstable and 74 
readily lost, with the issue muddied by ‘heteroresistance,’8,9 the inadequacy of disc 75 
testing and the variability of MICS with the test method.10 Despite these uncertainties 76 
it is clear and concerning that: (i) polymyxin-resistant mutants of carbapenemase-77 
producing Enterobacterales can cause outbreaks11 and (ii) that acquired mcr genes are 78 
widespread among Escherichia coli in food animals, e.g. in China.12   79 
The BSAC Resistance Surveillance Programme13 has tested colistin against 80 
Gram-negative bacteria (excepting inherently-resistant genera) since 2010/11. We 81 
present here the results, along with an investigation of the distribution and mode of 82 
resistance in Enterobacter cloacae complex isolates, where resistance proved to be 83 
unexpectedly frequent.   84 
 85 
Methods and materials 86 
Isolate collection 87 
Details of the BSAC Surveillance Programmes have been published previously.13 88 
Briefly, these programmes collected and tested c. 3000 bloodstream and lower 89 
respiratory tract infection (LRTI) isolates p.a. from centres across the UK and Ireland. 90 
The number of centres has varied from 25 to 40, with sites asked to collect fixed quotas 91 
of isolates per species group per year. There is some turnover of centres over time. 92 
Collection for the Respiratory Programme runs from October to September, to capture 93 
winter peaks in single years; the Bacteraemia Programme runs on the calendar year. 94 
Colistin began to be tested in October 2010 for LRTI isolates and January 2011 for 95 
bacteraemia isolates. Bacteraemia isolates were collected and tested by PHE’s 96 
Antimicrobial Resistance and Healthcare Associated Infections Reference Unit 97 
(AMRHAI) throughout: LRTI isolates were collected and tested by Quotient 98 
BioResearch (LGC Group, Fordam, Newmarket, UK) until the 2012/13 year and 99 
thereafter by AMRHAI.   100 
 101 
Laboratory methods 102 
The analysis straddles a period when species identification moved from API20E® strips 103 
(bioMerieux, Basingstoke, UK) to MALDI-ToF (Bruker, Bremen, Germany); this 104 
change was introduced during the 2011-12 LRTI and 2012 Bacteraemia surveillances.  105 
In general, the direct colony method was used for MALDI-ToF, though the extraction 106 
method was employed for subsets of isolates (see Results). MALDI-ToF identification 107 
software was updated as new versions were released - MBT DB-5627 (V.4) was 108 
employed for most testing. MICs were routinely measured by BSAC agar dilution on 109 
IsoSensitest Agar (Oxoid, Basingstoke, UK), with results interpreted versus 2019 110 
EUCAST breakpoints, which score colistin as S <2 mg/L, R >2 mg/L for 111 
Enterobacterales. MICs were also determined by broth microdilution in Mueller Hinton 112 
broth for the subset of isolates where LPS structure was studied. Heteroresistance was 113 
defined as where isolated colonies ‘trailed’ in agar dilution or where tubes were 114 
‘skipped’ in broth microdilution.  115 
 116 
Comparison of colistin-resistant and -susceptible E. cloacae group isolates 117 
The first 50 colistin-resistant isolates collected across both surveillances in 2010-12 118 
were compared, in a 1:1 case : control study, with 50 randomly-selected colistin-119 
susceptible isolates from the same centres in the same years.   120 
WGS was undertaken using Illumina methodology, with phylogenetic analyses 121 
based on core genomes; the read length was 2x100bp and a Nextera XT DNA library 122 
Prep kit was used. Illumina pair-end sequence reads were mapped onto the genome of 123 
the type strain, E. cloacae ATCC13047 (GenBank accession no: NC_014121.1) using 124 
the Phoenix algorithm.14 SNPs were called and filtered using the Genome Analysis 125 
Toolkit v2.0.15 Maximum likelihood analyses were undertaken based on the aligned 126 
SNPs, allowing 20% of Ns and gaps, using RAxML under a GTRCAT model with 500 127 
bootstraps.16 The best tree was drawn using the ITOL application.17 Sequence data 128 
supporting these analyses are in the process of being made available in the European 129 
Nucleotide Archive, under project accession number PRJEB35697. 130 
The ability to metabolise carbon and energy sources was analysed using the 131 
BIOLOG system (Biolog, Inc., Hayward, Ca., USA) with the PM1 MicroPlate™ test 132 
panel. Bacteria were grown overnight on CLED agar, then resuspended and loaded 133 
according to the manufacturer’s directions. Results were recorded as growth curves by 134 
the OmniLog® automated incubator reader then analysed using the OmniLog® Data 135 
Collection system. 136 
 137 
LPS analysis 138 
Lipid A modifications were investigated using MALDI-ToF mass spectrometry (MS). 139 
Bacteria were grown overnight in LB medium without antibiotic pressure, then 140 
sedimented and washed thrice in 10 ml phosphate buffer (PB, 10 mM Na2HPO4, 1.7 141 
mM KH2PO4). The final pellets were freeze-dried overnight then lipid A was extracted 142 
as previously described.18 After de-salting, 2-l lipid A aliquots were loaded onto the 143 
polished steel target of the MS instrument, air dried and covered by 1 μl of 2,5-144 
dihydroxybenzoic acid matrix (Sigma Aldrich, Gillingham, UK) dissolved in 0.1 M 145 
aqueous citric acid, and allowed to air dry. Finally, the target was inserted in an 146 
Autoflex MALDI-ToF spectrometer (Bruker). Data acquisition and analysis were 147 
performed using the Flex Analysis software.  148 
 149 
Statistical methods 150 
Trends in resistance prevalence were modelled by logistic regression using robust 151 
standard errors to allow for clustering by year (e.g. due to experimental variation and 152 
batch testing) and expressed as odds ratios; P values 0.05 were taken as moderate 153 
evidence for trend. P0.05 was also considered moderate evidence for independent 154 
prediction of resistance by factors such as isolate source (blood or respiratory infection) 155 
and identity. Fisher’s exact test was used to assess association between WGS group and 156 
substrate utilisation or colistin resistance, with Bonferroni adjustment for multiple 157 
testing. Clustering of metabolic capabilities was investigated by k-means and compared 158 
with hierarchical clustering by average linkage, using simple matching in both cases, 159 
and with distinctness of clustering indicated by the Caliński-Harabasz stopping rule 160 
(pseudo-F) index.  161 
 162 
Results 163 
Distribution of colistin resistance in Enterobacterales 164 
Annual rates of colistin resistance among bloodstream and LRTI Escherichia coli and 165 
Klebsiella species (including K. aerogenes) generally remained below 2% (Table 1). 166 
Resistance was more prevalent in the E. cloacae complex, and further work 167 
concentrated on this unexpected observation.  168 
The prevalence of colistin resistance among bloodstream E. cloacae complex 169 
isolates increased from 5.7% and 8.1% in 2011 and 2012, respectively, to 15.9% and 170 
13.4% in 2016 and 2017, respectively; logistic regression indicated prevalence 171 
increasing by a factor (odds ratio) of 1.19 per year (95% CI 1.07 to 1.32; p=0.001). 172 
Resistance rates for LRTI E. cloacae complex isolates also were higher than for other 173 
Enterobacterales species, but lacked the upward trend seen in bacteraemia (odds ratio 174 
per year 0.91 with 95% CI 0.80 to 1.05; p=0.19); rather, resistance prevalence was 175 
highest in the first year at 20% and thereafter fluctuated between 4.4% and 11.3%. 176 
Logistic regression models did not support the source of the isolate (blood/respiratory) 177 
as an independent predictor of colistin resistance after adjusting for species group. 178 
MICs, by agar dilution, for the resistant isolates straddled between 4 and >64 mg/L, 179 
compared with a sharp mode of 0.5 to 1 mg/L for susceptible isolates (Table 2).  180 
Resistant isolates were collected from widely scattered sites and did not reflect 181 
local outbreaks: 20/40 collecting sites submitted resistant isolates in Year 1 (i.e. 182 
2010/11 for Respiratory and 2011 for Bacteraemia) 17/40 in Year 2, 15/40 in Year 3, 183 
14/40 in Year 4, 17/40 in Year 5, 20/25 in Year 6 and 13/25 in Year 7.  184 
 According to their manufacturers, neither MALDI-TOF nor API20E® strips 185 
give reliable species identification within the E. cloacae complex. Nevertheless, and 186 
strikingly, over 85% of isolates with MICs 0.25 to 1 mg/L identified as E. cloacae 187 
species on first test, whereas, among isolates with higher MICs (including 2 mg/L, as 188 
the top border of susceptible), the proportion identified as E. cloacae was diminished: 189 
among those with MICs >64 mg/L only 24% identified as E. cloacae whereas 40% 190 
identified as E. asburiae (Table 2).  191 
 There were only minor differences among the source patients for the colistin-192 
resistant and -susceptible Enterobacters concerning sex (58.2% male versus 61.8%, 193 
respectively), age distribution (<4 years, 13.0% versus 10.3%, respectively; >60 years, 194 
31.7% versus 30.0%, respectively) or ICU location (16.4% versus 11.5%). Resistance 195 
to several comparator antibiotics was less prevalent among the colistin-resistant than 196 
colistin-susceptible isolates, including for third-generation cephalosporins (16.4% 197 
versus 23.2%), ciprofloxacin (6.2% versus 10.3%), gentamicin (2.3% versus 5.7%) and 198 
piperacillin/tazobactam (11.9% versus 14.7%). Only a single (colistin-susceptible) 199 
isolate was resistant to carbapenems. The proportions of isolates that were non-200 
susceptible to the various comparators was broadly stable across the surveillance period 201 
reviewed.19  202 
  203 
Case : control comparison of colistin-resistant and -susceptible E. cloacae 204 
A detailed study of the first 50 colistin-resistant Enterobacter isolates received was 205 
undertaken. These were from the 2011 and 2012 bacteraemia series and the 2010/11 206 
and 2011/12 respiratory series and were compared with 50 colistin-susceptible controls, 207 
randomly selected from among isolates collected at the same sites in the same period. 208 
As in later periods, the resistant isolates came from multiple sites, including 33 of the 209 
45 hospitals contributing isolates during the 2-years; 39 were from hospitals in England, 210 
six from Ireland, and three each from Scotland and Wales. The maximum number of 211 
resistant Enterobacters from any site was four (one site), with four further sites each 212 
contributing three isolates. The susceptible controls were from 28 sites, with no more 213 
than four from any one site. 214 
 WGS was performed on all 50 resistant isolates and 45/50 susceptible controls 215 
and an MIC distribution for these is included in Table 2; sequencing failed for the 216 
remaining 5 susceptible organisms. Analysis of the resulting data divided the 95 217 
sequenced organisms into seven Genogroups, designated A-G, with a single outlier (fig. 218 
1). Most (7/9) isolates in Genogroup A were colistin resistant, as were all those in 219 
Genogroups B (n=9), C (n=16), and D (n=15). By contrast, resistance was seen in only 220 
1/5 Genogroup E isolates, 2/26 Genogroup F isolates and 0/14 of Genogroup G. The E. 221 
cloacae type strain NCTC10005/ ATCC13047 was colistin resistant (MIC 8 mg/L) and 222 
fell into Genogroup D; the E. asburiae type strain NCTC12123/ATCC35953 fell into 223 
Genogroup C but, exceptionally for this Genogroup, was colistin susceptible (MIC, 1 224 
mg/L). None of the sequenced isolates carried acquired mcr genes. 225 
 Triplicate MALDI-ToF identification tests, using the extraction method and the 226 
MBT DB-5627 (V.4) database, were performed on the 95 sequenced isolates. 227 
Consistent identifications with all three replicates agreeing as E. cloacae dominated in 228 
Genogroups D, E, F and G whereas members of Genogroups A, B and C were more 229 
likely to identify repeatedly as E. asburiae, or to give a mixture of identifications as E. 230 
cloacae and E. asburiae (Table 3). 231 
 Carbon source utilisation profiles were obtained for 93/100 isolates; tests for 232 
the remaining 7 isolates failed.  The isolates with profiles obtained included 43 of the 233 
45 sequenced colistin-susceptible organisms and 44/50 sequenced colistin-resistant 234 
organisms (Table 3). Further analysis, below, was based on these 87 isolates for which 235 
we had both sequence and carbon source data: it excludes 6 isolates for which we had 236 
carbon source data only and 7 for which we had sequence data only.  237 
Strong relationships between Genogroup and metabolic profile were evident. 238 
Thus, L-fucose utilisation was seen for 36/38 Genogroup F and G isolates, also 3/5 in 239 
Genogroup E, whereas 42/43 isolates in Genogroups A-D tested could not use this 240 
sugar. The ability to utilise glucuronamide also was largely specific to Genogroup F 241 
and G, with 16/38 isolates positive versus 2/49 for all other Genogroups combined.  242 
Adonitol utilisation was unique to Genogroup F, though only seen for 19/25 group 243 
members; the ability to utilise lyxose also was largely specific to Genogroup F, with 244 
12/25 isolates positive versus 8/62 for all other Genogroups combined. By contrast (i) 245 
the ability to utilise myo-inositol was near-universal across Genogroups A-E, with 246 
46/48 isolates positive compared with 4/38 in Genogroups F and G combined, (ii) the 247 
ability to utilise formic acid was widespread in Genogroups A, B,  C and E, with  34/36 248 
isolates positive versus 2/51 for all other Genogroups combined, and (iii) the ability to 249 
utilise -keto-glutaric acid was seen in over half the Genogroup A and B isolates (5/8 250 
and 6/9, respectively) versus 10/70 for all other groups combined. In other cases 251 
inability to use a substrate was associated with particular Genogroups: thus 0/13 252 
Genogroup G isolates utilised D-serine compared with 66/74 isolates from other 253 
Genogroups and only 2/14 Genogroup C isolates utilised D-galactonic acid--lactone 254 
compared with 71/73 isolates from all other Genogroups combined.   255 
 Both the hierarchical statistical method and k-means clustering indicated that 256 
Genogroups F and G (considered as a pair) were distinct from other Genogroups in their 257 
substrate utilisation. Metabolic differences among the remaining Genogroups were not 258 
clear-cut by statistical analyses. Since Genogroups F and G also comprised the great 259 
majority of the colistin-susceptible isolates there were strong associations also between 260 
metabolic profile and susceptibility, which was strongly linked (adjusted p <0.01) with 261 
the ability to utilise L-fucose, adonitol, and glucuronamide whereas the ability to utilise 262 
formic acid and myo-inositol was associated with resistance (p <0.01).   263 
 Polysorbate (Tween®) utilisation was more widespread among colistin-resistant 264 
isolates than -susceptible isolates, with this difference more marked for polysorbate 80 265 
(adjusted p=0.004) than polysorbate 40 (adjusted p=0.011) or polysorbate 20 (adjusted 266 
p = 0.439). Underlying these observations were two key traits: (i) that the great majority 267 
of Genogroup G isolates (colistin-susceptible) lacked the ability to utilise any 268 
polysorbate whereas all the predominantly colistin-resistant Genogroups (A-D) 269 
comprised organisms that mostly could utilise polysorbates 20 and 40 and, (ii) that 270 
Genogroup D (colistin resistant) and F (mostly colistin-susceptible) isolates commonly 271 
utilised polysorbates 20 and 40 but not polysorbate 80.   272 
 273 
LPS analysis  274 
One or two representatives of each Genogroup cluster were selected for LPS 275 
characterisation along with the E. cloacae type strain NCTC10005/ATCC13047, which 276 
was colistin resistant and belonged to Genogroup D. Broth dilution MICs were 277 
determined for these isolates in addition to the initial agar dilution values. The values 278 
in broth were higher, particularly for the more resistant organisms but only in one case 279 
was there a categorical disagreement: isolate EN104606 was found susceptible on agar 280 
(and thus atypical of its Genogroup [A]) but heteroresistant in broth (Table 4). 281 
MALDI-TOF MS analysis of the lipid A of E. cloacae 282 
NCTC10005/ATCC13047 (fig. 2), grown without antibiotic pressure, revealed 283 
prominent molecular ion peaks at 1387, 1797, 1840 and 2063 m/z. The 1387 m/z peak 284 
is consistent with tetra-acylated lipid A fragmentation product, while the 1824 m/z peak 285 
is consistent with hexa-myristoylated (C14) lipid A forms resembling those found in K. 286 
pneumoniae, E. coli and Yersinia enterocolitica.20,21,22 The species at 1797 m/z is 287 
consistent with a penta-myristoylated lipid A substituted with an additional C12 acyl 288 
chain (fig. 2). Modified forms of the 1824 and 1797 m/z molecular ions were also 289 
present, reflecting addition of a hydroxyl group (typically catalysed by LpxO; m/z 1840 290 
to 1824) or a palmitate group (typically catalysed by PagP) (m/z 2063 to 1824).24 These 291 
results indicate that the lipid A of strain ATCC13407 is complex and modified by 2-292 
hydroxylation and palmitoylation. No molecular ions consistent with Ara4N or 293 
phosphoethanolamine substitutions were observed using bacteria grown in drug-free 294 
LB; an analysis of lipid A modifications under other in vitro growth conditions and in 295 
vivo will be reported elsewhere.  296 
Lipid A analyses for representatives of the various DNA Genogroups are 297 
summarised in Table 4. The 1824 m/z molecular ion was abundant in the lipid A of 298 
most isolates except N2878 (Genogroup E) (Table 4). Most of the isolates produced 299 
penta-myristoylated lipid A with an additional C12 acyl chain (1797 m/z), although the 300 
abundance of this ion varied (Table 4 and fig. S1). In general, more complex patterns, 301 
with a greater number of molecular species, particularly including modified forms with 302 
hydroxylation and palmitoylation, were observed for isolates with colistin resistance or 303 
heteroresistance (Table 4).     304 
 305 
Discussion 306 
Colistin began to be tested in the BSAC Surveillance in 2010 and we reviewed 307 
subsequent resistance trends among Enterobacterales. Resistance prevalence remained 308 
under 2% in almost all years for E. coli and Klebsiella (including K. aerogenes) but 309 
was higher for bloodstream and respiratory E. cloacae complex isolates, with a strong 310 
increasing trend for bloodstream, but not respiratory, organisms. The colistin-resistant 311 
E. cloacae isolates were widely scattered in time and place and did not represent 312 
outbreak clones, as confirmed by WGS. Rather, they largely belonged to Genogroups 313 
A-D and had metabolic differences from members of Genogroups F and G, which, 314 
along with Genogroup E, encompassed the great majority of colistin-susceptible E. 315 
cloacae. Within Genogroups A-D, 47/49 isolates were colistin resistant compared with 316 
3/45 isolates in Genogroups E-G.    317 
Relating our Genogroups to the established taxonomy for the E. cloacae 318 
complex proved challenging. Although MALDI-ToF does not reliably identify within 319 
the E. cloacae complex it was striking that isolates belonging to three of the four 320 
predominantly colistin-resistant Genogroups (A, B and C but not D) were more likely 321 
to identify as E. asburiae, or to give a mixture of E. asburiae and E. cloacae 322 
identifications, with this likelihood rising with the colistin MIC. Conversely, isolates 323 
belonging to the predominantly susceptible Genogroups E, F and G largely identified 324 
as E. cloacae, as did the (mostly resistant) members of Genogroup D. The simple notion 325 
of intrinsic colistin resistance in E. asburiae and susceptibility in E. cloacae is however 326 
refuted by the literature25 and by the type strains E. asburiae NCTC12123/ATCC35953 327 
(Group C, MIC 1 mg/L) and E. cloacae NCTC10005/ATCC13047 (Group D, MIC 8 328 
mg/L) showing the converse pattern. 329 
Grimont and Grimont write, in Bergey’s Manual of Determinative 330 
Bacteriology26 that ‘typical’ E. cloacae largely fall into their genomic group 3. This 331 
putatively corresponds to our Genogroups F and G, as evidenced (i) by the dominance 332 
of these genomic groups among ‘typical’ colistin-susceptible isolates and (ii) by ability 333 
of Genogroup F and G isolates to utilise adonitol and fucose, which are not utilised by 334 
Bergey’s other genomic groups - and inability to utilise myo-inositol- a substrate 335 
Bergey notes as less reliably used by group 3 than by other groups. Our Genogroups A-336 
D predominantly comprised organisms selected on the basis of their colistin resistance 337 
– a trait unlikely to be common in series selected on other criteria –so it is perhaps 338 
unsurprising that they do not obviously match to other genomic groups described by 339 
Grimont and Grimont. We agree that the ‘type strain’ E. cloacae 340 
NCTC10005/ATCC13047 is poorly representative, as it clusters apart from typical (i.e. 341 
F and G / group 3) isolates, falling into our Genogroup D and Grimont and Grimont’s 342 
group 1. 343 
In general, colistin resistance depends on the production of modified lipid A 344 
molecules with substitutions that reduce the electronegative potential of the LPS. The 345 
lipid A profiles of selected isolates representing the various E. cloacae clusters were 346 
investigated after growth without antibiotic pressure to assess if isolates displaying high 347 
resistance or heteroresistance to colistin were "primed" for resistance. Compared with 348 
susceptible isolates, the resistant and heteroresistant organisms examined exhibited 349 
complex lipid A patterns, more often having forms with 2-hydroxylation and 350 
palmitoylation, which typically are generated by LpxO and PagP enzymes. These 351 
modifications are associated, in several bacteria, with enhanced resistance to 352 
polymyxins and vertebrate antimicrobial peptides,27-29 and they are predicted to reduce 353 
permeability across the outer membrane.29 The expression of lpxO and pagP genes is 354 
regulated by the master two-component system PhoPQ,30,31 which controls enzymes 355 
involved in the remodelling of the LPS, including those that add Ara4N and 356 
ethanolamine. Although expression of lpxO and pagP homologues was not investigated 357 
here, our results suggest that the heteroresistant isolates have a higher basal level of 358 
expression of these genes, which might confer some immediate protection against 359 
colistin, with this  further enhanced by full activation of the PhoPQ regulon in the 360 
presence of the antibiotic. Recent work suggests that LpxO expression is also regulated 361 
by the metabolic and redox status of the bacterium,32 suggesting that heteroresistance 362 
could also reflect bacterial adaptation to metabolic stress.        363 
The study has several limitations, besides the taxonomic uncertainty within the 364 
E. cloacae complex. First, agar dilution was used for susceptibility testing whereas 365 
broth microdilution is now recommended by EUCAST as more reliable for resistance 366 
detection, though this view is disputed by others.10 At most, however, this may have 367 
led us to underestimate the prevalence and degree of resistance; for the isolates 368 
subjected to LPS analysis (Table 4) broth MICs were determined, in addition to the 369 
original agar values. The broth values typically were higher but, only in one case did 370 
this lead to a categorical disagreement: isolate EN104606 was found susceptible – and 371 
so atypical of Genogroup A, to which it belonged, by agar dilution – but proved 372 
heteroresistant in broth testing.  A second caveat is that colistin MICs were very widely 373 
distributed among resistant isolates and an organism with an MIC of 4 mg/L may have 374 
more in common with a ‘susceptible’ E. cloacae than one with an MIC of >64 mg/L. 375 
Third, this project had a long gestation and WGS and metabolic profiling were 376 
exclusively done on isolates from the early years. It is plausible that proportions of the 377 
different Genogroups changed subsequently and that expansion of one or more of this 378 
predominantly resistant groups A-D, with particular pathogenic traits, explains the 379 
dichotomy in trends for bloodstream and LRTI isolates. 380 
The practical importance of our observations are uncertain. On the one hand, E. 381 
cloacae is among the more frequent Gram-negative opportunists and, along with E. coli 382 
and K. pneumoniae, is among the major hosts of carbapenemases, forcing colistin use. 383 
Accordingly, any potential ‘loss’ of colistin, e.g. via an expansion of one or more 384 
resistant Genogroup, would potentially be concerning. On the other hand, intravenous 385 
polymyxins are now being supplanted by -lactamase inhibitor combinations, including 386 
ceftazidime/avibactam and meropenem/vaborbactam, which are  less toxic and  appear 387 
more efficacious against Enterobacterales with KPC (and OXA-48 in the case of 388 
ceftazidime/avibactam) carbapenemases.33 If these and coming analogues including 389 
imipenem/relebactam, cefiderocol and cefepime/zidebactam live up to their promise, 390 
the renaissance of intravenous polymyxins may prove to be a brief interlude, and the 391 
erosion of Enterobacter coverage less than catastrophic.  392 
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Table 1.  Rates of resistance to colistin among Enterobacterales species collected in the BSAC Surveillance Programme 528 
 529 
 Proportion of isolates found resistant to colistin, 2 mg/L 
 Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 
Bacteraemia 2011 2012 2013 2014 2015 2016 2017 
Enterobacter cloacae group* 9/158 13/161 12/160 11/172 17/169 27/170 21/157 
K. aerogenes (E. aerogenes) 0/14 0/36 0/44 0/36 1/41 1/29 1/29 
K. pneumoniae 2/200 4/196 1/213 1/205 8/206 2/186 3/164 
K. oxytoca 0/56 0/55 0/53 0/55 0/57 0/58 0/57 
E. coli 2/522 3/520 6/539 3/547 3/548 1/496 2/477 
LRTI 2010/11 2011/12 2012/13 2013/14 2014/15 2015/16 2016/17 
Enterobacter cloacae group*  21/105 7/93 10/85 3/68 9/90 10/90 8/71 
K. aerogenes (E. aerogenes) 0/34 0/42 0/40 0/22 0/23 0/35 0/32 
K. pneumoniae 4/145 4/166 2/140 3/150 4/187 0/152 2/141 
K. oxytoca 3/71 1/73 1/56 0/68 0/63 1/68 0/49 
E. coli 6/274 1/239 0/250 0/255 0/244 0/230 3/277 
Bold text indicates rates >2% 530 
*Enterobacter cloacae group comprises: Enterobacter cloacae, Enterobacter asburiae, Enterobacter hormaechei, Enterobacter kobei, 531 
Enterobacter ludwigii and Enterobacter nimipressuralis. 532 
Until 2014/15 (respiratory) and 2015 (bacteraemia) isolates were collected from up to 40 centres across the UK and Ireland and, thereafter from 533 
up to 25 centres. 534 
  535 
Table 2.  Species identification within the E. cloacae group in relation to colistin MIC: all isolates.  536 
 537 
Colistin MIC (mg/L) 
Whole collection 2010-17:  (%) isolates identified as: Isolates 
sequenced 
Total E. cloacae E. asburiae Other named 
No species-level 
identification 
0.25 (S) 184 (100) 169 (91.8) 8 (4.3) 6 (3.3) 1 (0.5) 21 
0.5 (S) 990 (100) 880 (88.9) 54 (5.5) 3 (0.3) 53 (5.4) 23 
1 (S) 360 (100) 311 (86.4) 20 (5.6) 2 (0.6) 27 (7.5) 1 
2 (S, breakpoint)) 37 (100) 24 (64.9) 9 (24.3) 0 (0) 4 (10.8)  
4 (R) 26 (100) 13 (50.0) 10 (38.5) 1 (3.8) 2 (7.7) 7 
8 (R) 31 (100) 21 (67.7) 6 (19.4) 0 (0) 4 (12.9) 8 
16 (R) 25 (100) 17 (68.0) 2 (8.0) 3 (12.0) 3 (12.0) 12 
32 (R) 21 (100) 10 (47.6) 2 (9.5) 1 (4.8) 8 (38.1)  
64 (R) 75 (100) 18 (24.0) 30 (40.0) 2 (2.7) 25 (33.3) 23 
Total 1749 (100) 1463 (83.6) 141 (8.1) 18 (1.0) 127 (7.3) 95a 
 538 
a Omits 5 isolates for which sequencing failed 539 
Note: From 2010 to 2012 identification was by API20E strips; subsequently identification was by MALDI-ToF using the colony method (see 540 
text).  Neither method gives reliable definitive identifications within the E. cloacae complex and ‘identifications’ were apt to vary upon repeat 541 
testing; nevertheless the trend to higher proportion identified as E. asburiae or not identified to species level at higher colistin MIC is clear.   542 
543 
Table 3.  Metabolic traits in relation to colistin status and WGS-based Genogroup 544 
 In relation to 
Colistin MIC (mg/L) 
In relation to Genogroup  
 <2 >2 A B C D E F G Outlier 
No. group 43 44 8 9 14 12 5 25 13 1 
No. able to metabolise 
Dulcitol 3 8 1 5 1 1 0 2 0 1 
D-Serine 27 39 8 5 13 12 5 22 0 1 
L-Fucose 37 3 0 0 0 1 3 23 13 0 
Formic acid 6 30 8 9 12 2 5 0 0 0 
D-Galactonic acid--lactone  42 31 8 8 2 12 5 25 13 0 
L-Rhamnose 43 38 8 9 8 12 5 25 13 1 
D-Melibiose 36 42 7 9 13 12 5 24 8 1 
-Keto-glutaric acid 6 15 5 6 3 0 0 6 1 0 
-Methyl-D-galactoside 37 42 7 9 13 12 5 24 8 1 
Lactulose 20 13 6 1 5 2 2 9 8 0 
-Hydroxy butyric acid 9 4 1 0 2 1 1 5 3 0 
Adonitol 17 2 0 0 0 0 0 19 0 0 
 545 
 546 
Substrates tested and metabolised by >90% of both colistin-susceptible and –resistant isolates: acetic acid, N-acetyl-D-glucosamine, N-acetyl--547 
D-mannosamine, adenosine,  D-alanine, L-alanine, L-alanyl-glycine, L-arabinose, L-asparagine, L-aspartic acid, bromosuccinic acid, D-cellobiose, 548 
citric acid, 2-deoxy adenosine, D-fructose, D-fructose-6-phosphate, fumaric acid, L-galactonic acid--lactone D-galacturonic acid, D-galactose, D-549 
gluconic acid, -D-glucose, D-glucose-1-phosphate, D-glucose-6-phosphate, D-glucuronic acid, L-glutamic acid, L-glutamine, glycerol, D,L-550 
glycerol phosphate, glycyl-L-glutamic acid, glycyl-L-proline, m-hydroxy-phenylacetic acid, p-hydroxy-phenylacetic acid, inosine, L-lactic acid, 551 
Glycyl-L-aspartic acid 40 36 8 9 13 6 3 25 12 0 
myo-Inositol 9 42 7 9 13 12 5 4 0 1 
Mono-methyl succinic acid 4 10 3 0 6 1 0 3 1 0 
L-Lyxose 16 4 0 2 1 0 1 12 3 1 
Glucuronamide 16 2 1 0 1 0 0 9 7 0 
Phenylethylamine 5 2 0 1 0 0 0 5 1 0 
Polysorbate (Tween®) 20 23 35 7 9 11 8 5 16 2 0 
Polysorbate (Tween®) 40 20 37 7 9 11 10 5 12 3 0 
Polysorbate (Tween®) 80 10 28 6 8 10 4 5 4 1 0 
Identifications: based on top scores by 3 tests by MALDI-ToF 
E. cloacae in 3/3 cases 36 15 2 0 0 10 4 23 12 0 
E. asburiae  in 3/3 cases 0 17 2 4 10 1 0 0 0 0 
Mixed results 7 12 4 5 4 1 1 2 1 1 
-D-lactose, D,L-malic acid, L-malic acid, maltose, maltotriose, D-mannitol, D-mannose, -methyl-D-glucoside, methyl pyruvate, mucic acid, L-552 
proline,  pyruvic acid, D-ribose, D-saccharic acid, L-serine, D-sorbitol, succinic acid, sucrose, thymidine, L-threonine, D-trehalose, uridine and D-553 
xylose.  Compounds metabolised by <10% of both colistin-susceptible and –resistant isolates were acetoacetic acid, 2-aminoethanol, D-aspartic 554 
acid, D-glucosaminic acid, glycolic acid, glyoxalic acid, -hydroxy glutaric acid--lactone, keto-butyric acid, D-malic acid, 1,2 propanediol, 555 
propionic acid, D-psicose, m-tartaric acid, D-threonine, tricarballylic acid and tyramine. 556 
  557 














1387 1797 1824 1840 2036 2063 
EN104606 A 0.5 4 to 32a + + + + + + 
EN2852 A 256 512 + + + + + + 
EN104107 B 4 512 + + + - ?c ?c 
EN105227 B 8 >1024 + + + + + + 
EN100708 C >32 256 + + + - - - 
EN105406 C >32 
32 to 
1024a 
+ + + + + + 
EN2692 D 16 512 + + + + + + 
NCTC/10005 
ATCC13047 
D 8 128 + + + + + + 
EN2720 D 4 
8 to 
512a 
+ + + + + + 
EN2878 E 0.5 2 - + - - + - 
EN2889 F 0.5 2 + + + + - + 
EN104619 F 0.25 2 + + + + - + 
EN104003 F 8 4 - - + - - - 
EN115203 G 0.25 2 + + + - - - 
 561 
a Substantial heteroresistance / trailing end-points seen 562 
b Proposed lipid A composition of each of the molecular ions (see fig. S1 for detailed 563 
spectra):  564 
 1387; Tetra-acyl (3x C14:0(3-OH), 1x C14:0), 2P 565 
 1797; Hexa-acyl (4x C14:0(3-OH), 1x C14:0, 1x C12:0), 2P 566 
 1824; Hexa-acyl (4x C14:0(3-OH), 2x C14:0), 2P 567 
 1840; Hexa-acyl (4x C14:0(3-OH), 1x C14:0, 1x C14:0(3-OH), 2P 568 
 2036; Hepta-acyl (4x C14:0(3-OH), 1x C14:0, 1x C12:0, 1x C16:0), 2P 569 
 2063; Hepta-acyl (4x C14:0(3-OH), 2x C14:0, 1x C16:0), 2P 570 
c Molecular ion could not be confirmed due to background noise 571 
Figure Legends 572 
Figure 1. Dendrogram showing relatedness of the 95 E. cloacae group isolates 573 
successfully sequenced together with type strains E. cloacae 574 
NCTC10005/ATCC13047 (Genogroup D) and E. asburiae NCTC12123/ATCC35953 575 
(Genogroup C).  576 
 577 
Footnotes 578 
A-G, Genogroups described in the text. 579 
Open circle, colistin-susceptible isolate; solid circle, colistin-resistant isolate 580 
Open triangle, respiratory isolate; solid triangle, bloodstream isolate 581 
 582 
Figure 2.  MALDI-TOF mass spectrometry and predicted lipid A species in the E. 583 
cloacae ATCC13047 type strain. The prominent molecular ion in the spectrum (m/z 584 
1824) corresponds to a di-phosphorylated hexa-acylated lipid A, which is identical to 585 
that described for Klebsiella pneumoniae.22 Dotted squares indicate the following 586 
modifications likely responsible for the observed mass shifts: I, elimination of the 587 
myristoxymyristoyl group (m/z 1387) by fragmentation of m/z 1824);23 II, 588 
hydroxylation of the C'-2 myristoyl-oxo-acyl chain (m/z 1840);22 III, C'-2 lauryl-oxo-589 
acyl chain  (m/z 1797); IV, palmitoylation of the C-1 acyl-oxo-acyl chain (m/z 2063); 590 
V,  hydroxylation of the C'-2 myristoyl-oxo-acyl chain plus palmitoylation of the C-1 591 













Figure 2.   597 
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